Tema Etfs LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Tema Etfs LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 21,635 shares of the medical research company’s stock, valued at approximately $1,602,000.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. Crowley Wealth Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. Millstone Evans Group LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $30,000. Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $54,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $62,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.3%

Edwards Lifesciences stock opened at $77.92 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $45.71 billion, a price-to-earnings ratio of 11.18, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company’s fifty day moving average price is $72.08 and its two-hundred day moving average price is $71.75.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the business posted $0.66 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 5,980 shares of the company’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the sale, the chief executive officer now owns 58,284 shares of the company’s stock, valued at $4,366,054.44. This trade represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,192 shares of company stock worth $4,709,454 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of several recent analyst reports. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a research note on Friday, April 25th. Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $79.60.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.